ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Imipenem resistance inNew microbes and new infections · 2026
   Review
2. Enhanced antibacterial activity of antimicrobial peptide-antibiotic combinations against multidrug-resistant bacteria.FEMS microbes · 2026
   Review
3. Multidrug resistance and carbapenemase producing Enterobacteriaceae isolated from clinical samples, Addis Ababa, Ethiopia: A cross-sectional study.PloS one · 2026
   Article
4. High Prevalence of ESBL-Producing Enterobacteriaceae and Antimicrobial Resistance Patterns in a Tertiary Care Hospital in Mogadishu, Somalia: A Retrospective Cross-Sectional Study.Infection and drug resistance · 2026
   Article
5. Management practices and mortality predictors among Klebsiella pneumoniae infections across Lebanese hospitals: a multicenter retrospective study.BMC infectious diseases · 2025
   Observational
6. Effectiveness of Carbapenem-Sparing Antibiotics Versus Carbapenems for Treating Non-Bacteremic Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Infections.Infection and drug resistance · 2025
   Article
7. Cefiderocol in Combating Carbapenem-ResistantBiomedicines · 2024
   Review
8. Prevalence of carbapenem-resistantSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
   Article
9. Risk factors associated with multidrug-resistant Klebsiella pneumoniae infections: a multicenter observational study in Lebanese hospitals.BMC public health · 2024
   Observational
10. Prevalence and genetic characterization of clinically relevant extended-spectrum β-lactamase-producingFrontiers in antibiotics · 2023
    Review
11. Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistantAnnals of medicine · 2022
    Article
12. The Prevalence of Multidrug-ResistantHealthcare (Basel, Switzerland) · 2022
    Article
13. Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2022
    Article
14. Antibiotics and Antimicrobials Resistance: Mechanisms and New Strategies to Fight Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2022
    Article
15. Antibiotic Sensitivity ofInternational journal of clinical practice · 2022
    Article
16. Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-ResistantInfection and drug resistance · 2022
    Article
17. Antimicrobial Resistance Patterns and ESBL of Uropathogens Isolated from Adult Females in Najran Region of Saudi Arabia.Clinics and practice · 2021
    Article
18. Urinary Tract Infections in Elderly Patients: A 10-Year Study on Their Epidemiology and Antibiotic Resistance Based on the WHO Access, Watch, Reserve (AWaRe) Classification.Antibiotics (Basel, Switzerland) · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as